RecruitingNCT07339254

Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study

Experiences With and Attitudes Towards Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer (NSCLC) - A Single Center, Survey-Based Study

Sponsor

University of Southern California

Enrollment

40 participants

Start Date

Mar 12, 2026

Study Type

OBSERVATIONAL

Conditions

Lung Non-Small Cell Carcinoma

Summary

This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a survey-based study — not a treatment trial — looking at the experiences and attitudes of non-small cell lung cancer (NSCLC) patients toward a class of cancer drugs called immune checkpoint inhibitors (ICIs), such as pembrolizumab or nivolumab. The goal is to better understand what patients think and feel about these treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with non-small cell lung cancer (NSCLC) confirmed by biopsy - You are currently receiving an immune checkpoint inhibitor (such as atezolizumab, cemiplimab, durvalumab, nivolumab, or pembrolizumab) and have completed at least one cycle **You may NOT be eligible if...** - You are not able to consent for yourself - You have not yet completed your first cycle of immunotherapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNon-Interventional Study

Non-interventional study

Locations(2)

Los Angeles General Medical Center

Los Angeles, California, United States

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07339254

Related Trials

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NCT042678481149 locations

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NCT06498635227 locations

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

NCT073236411 location

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

NCT0728803413 locations

Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers

NCT039481001 location